John F. Crowley Chairman & Chief Executive Officer
John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc. John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children's lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.
John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, "The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children." The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope and Joy.
John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He serves on the Executive Committee of the National Board of Directors of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. He also serves on the Board of Directors of Scioderm, Inc. John is a Henry Crown Fellow at the Aspen Institute.
David Allsop Senior Vice President, International
David Allsop joined Amicus in April 2015 as Senior Vice President, International. Mr. Allsop brings over 27 years of international General Management and commercial experience in the biopharmaceutical industry between Biogen Idec and Janssen-Cilag, with extensive operational and strategic leadership in the areas of neurology, autoimmune diseases, hemophilia, gastroenterology, dermatology, and renal. He has successfully launched three blockbuster therapies internationally as well as many other therapies both nationally and internationally. Mr. Allsop has both direct and indirect experience in securing market access and reimbursement in the European Union and international markets.
Prior to joining Amicus, Mr. Allsop was instrumental in building Biogen’s international commercial organization over the last 17 years. He most recently served as Senior Vice President, Europe and Canada, with full responsibility for the business and organization in those territories. While at Biogen he led the successful international launch of several products in the multiple sclerosis franchise, including Avonex®, Tysabri®, Fampyra®, Tecfidera® and Plegridy™ as well as taking responsibility for the hemophilia development organization. Prior to his tenure at Biogen, Mr. Allsop spent 10 years in roles of increasing responsibility at Janssen-Cilag, working in gastroenterology, dermatology and renal, including building and running a number of commercial units and taking responsibility for the Company’s largest brand in the United Kingdom.
William D. "Chip" Baird, III Chief Financial Officer
William D. "Chip" Baird joined Amicus Therapeutics in April 2012 as Chief Financial Officer. He brings over 15 years of experience in finance and strategic planning. Prior to Amicus Mr. Baird held roles of increasing responsibility for over 10 years at PTC Therapeutics, Inc. As Chief Financial Officer of PTC from April 2005 to April 2012, he was responsible for all areas of finance, investor and public relations, human resources, facilities and project management. During his tenure at PTC, he was instrumental in raising over $500 million through a combination of venture capital, non-dilutive grant funding, collaborations with industry-leading pharmaceutical and biotech companies, and debt financings. Previously, Mr. Baird worked at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002 and at First Union National Bank as a corporate underwriter from 1994 to 1997.
Mr. Baird received a B.S. from Georgetown University's Edmund A. Walsh School of Foreign Service and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.
Jay A. Barth M.D. Chief Medical Officer
Jay A. Barth joined Amicus Therapeutics in March 2014 as Chief Medical Officer. Dr. Barth brings to Amicus more than 15 years of experience in drug development, clinical research and medical affairs. Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC’s Senior Vice President, Clinical Development. In this role he led the clinical team and oversaw all global clinical development programs, focusing on rare diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc.
Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School of Medicine. He is a member of the American Gastroenterological Association, the American College of Gastroenterology, and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. He is also the author of numerous publications in the fields of medicine and clinical research.
Bradley L. Campbell President and Chief Operating Officer
Bradley L. Campbell joined Amicus in May 2006 and currently serves as President and Chief Operating Officer. He brings 15 years of experience in the biotech and pharmaceutical industries. Prior to Amicus, Mr. Campbell was with Genzyme Corporation, where he first served as Sr. Product Manager for Myozyme®, an enzyme replacement therapy for Pompe disease. He then became a Business Director in Genzyme Cardiovascular, responsible for business development, alliance management and commercial planning for their cardiac gene therapy programs. Mr. Campbell has also worked in sales & marketing for Bristol-Myers Squibb and as a business strategy consultant for Marakon Associates.
Mr. Campbell has been active in a number of philanthropic organizations and is an Executive Committee member and Past-President of the Board of Directors of the National Tay-Sachs and Allied Diseases (NTSAD) Association. He received his B.A. in Public Policy Studies from Duke University and his M.B.A. from Harvard Business School.
Jeffrey P. Castelli Ph.D. Vice President, Program Management and Portfolio Planning
Jeffrey P. Castelli joined Amicus in July 2005 and currently serves as Vice President, Program Management and Portfolio Planning. He brings 13 years of experience in program management, business operations, alliance management, and as a management consultant. Prior to joining Amicus, Dr. Castelli was a Manager at Health Advances LLC and previously served as a Business Development Analyst at Neose Pharmaceuticals Inc.
Dr. Castelli received a B.S. from West Chester University and a Ph.D. from the University of Pennsylvania.
Enrique Diloné joined Amicus in August 2009 and currently serves as Vice President, Technical Operations. He brings over 23 years of experience in drug development. Prior to joining Amicus, Dr. Diloné served as Executive Director of Quality and Analytics at NovaDel Pharma Inc., a specialty pharmaceutical company developing oral spray formulations, from February 2007 to August 2009. He served as Senior Director/Director of Analytical Operations at OSI/Eyetech Pharmaceuticals from February 2002 to December 2006. He also worked in several pharmaceutical development departments at Wyeth and Hoffmann-La Roche.
Dr. Diloné received a B.A. in Chemistry from New York University, and a Ph.D. and a M.S., both in Chemistry, from Seton Hall University. He graduated from Harvard Business School’s General Management Program in 2013, and is certified in U.S. Regulatory Affairs.
Hung Do Ph.D. Senior Vice President, Discovery Biology
Hung Do joined Amicus in December 2013 and currently serves as Senior Vice President, Discovery Biology. Dr. Do brings nearly 15 years of experience in the field of lysosomal storage diseases (LSDs) and enzyme replacement therapies (ERTs). Prior to joining Amicus, Dr. Do was a Co-founder and Chief Scientific Officer of Callidus Biopharma, a privately-held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof-of-concept for ERTs, and served as the project leader for a second-generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme, which was acquired by Genzyme.
Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University (mentored by Professor Arthur E. Johnson) and was a post-doctoral fellow in Hematology/Oncology at Emory University (Dr. John S. Lollar). Dr. Do utilizes his focused training in protein synthesis, folding & trafficking to develop better targeted therapeutic treatments for genetic diseases.
Dipal Doshi Senior Vice President, Business Planning and Development
Dipal Doshi joined Amicus Therapeutics in July 2014 as Senior Vice President, Business Planning and Development. He brings over 15 years of experience in the biotechnology and pharmaceutical industry. Prior to Amicus Mr. Doshi served as Senior Vice President at Auven Therapeutics, a healthcare private equity and pharmaceutical development company where he led or participated in the financing of several biotech and pharmaceutical platform companies. Mr. Doshi held significant operating roles in Auven Therapeutics' portfolio companies, including ADC Therapeutics and Spirogen (acquired by AstraZeneca). Previously, Mr. Doshi was the Head of Corporate Development for Catalent Pharma Solutions, a Blackstone Group company. He also worked in the Investment Banking Division of Merrill Lynch; held sales and marketing positions at Eli Lilly; and served as a business consultant for Oliver Wyman and Sapient Corporation. Mr. Doshi received a B.A. from Rutgers University and an M.B.A. from The Wharton School of the University of Pennsylvania.
Jayne C. Gershkowitz Vice President, Patient and Professional Advocacy and Public Policy
Jayne C. Gershkowitz joined Amicus in June 2006 and currently serves as Vice President, Patient and Professional Advocacy and Public Policy. She is a long-time patient advocacy professional with expertise in the rare disease community, specifically in the LSD space. Prior to joining Amicus, Ms. Gershkowitz served as Executive Director at the NTSAD Association, where she co-founded the LSD Research Consortium in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and established the NTSAD Research Initiative. Her earlier career experience encompasses newspaper journalism; corporate and non-profit marketing communications; and social services.
Ms. Gershkowitz is active in several organizations within the rare disease community as well as the broader biotech arena. She is a Co-founder and Chair of the Patient Advocacy Committee of BioNJ, and Vice President of Education of the Board of Directors of the NTSAD Association. She is currently a member of the Steering Committee of the Healthcare Institute of New Jersey; the Patient Advocacy and Access and Reimbursement Committees of the Corporate Alliance of the Global Genes RARE Project; and the Policy Working Group of the National Organization for Rare Disorders Corporate Council. Ms. Gershkowitz earned a degree in journalism from the the Newhouse School of Public Communications at Syracuse University and studied business administration at the Radcliffe Graduate Seminars Program.
John R. Kirk Sc.D. Vice President, Regulatory Affairs and Quality Assurance
John R. Kirk joined Amicus in January 2008 and currently serves as Vice President, Regulatory Affairs and Quality Assurance. He brings over 20 years of experience in global regulatory affairs and approval processes, and has a track record of establishing GMP and GCP quality systems. Prior to joining Amicus, Mr. Kirk served as Executive Director, Regulatory Affairs at Aegerion Pharmaceuticals, Inc. Mr. Kirk also held positions of increasing responsibility with Esperion Therapeutics, Inc. which was acquired by Pfizer. While employed at Warner-Lambert Co. and Pfizer, Mr. Kirk played a key role in several programs in the cardiovascular and inflammation therapeutic areas, including 12 years of participation in the Lipitor program.
Mr. Kirk received both a B.S. and a M.S. from Wright State University in Ohio. He also earned a Sc.D. in Health Outcomes Research at the Tulane University School of Public Health and Tropical Medicine, Department of Health Systems Management.
Kenneth W. Peist Esq. Vice President, Legal and Intellectual Property
Kenneth W. Peist, Esq., joined Amicus in December 2007 and currently serves as Vice President of Legal and Intellectual Property. He brings 15 years of legal experience in intellectual property, regulatory and transactional law. Prior to Amicus, he was part of the legal team at Bristol-Myers Squibb, where he performed due diligence on assets for in-licensing and out-licensing efforts, and advised senior executives in research and development on worldwide legal issues that cross both intellectual property and regulatory law. Mr. Peist’s previous work experience also includes a variety of legal positions at Vitae Pharmaceuticals and ExxonMobil. He also served as a scientist at the United States Environmental Protection Agency as well as laboratory supervisor at ENSECO Inc. and EMS Laboratories.
Mr. Peist received a B.S. in Biology with a minor in Chemistry from Old Dominion University. He earned a J.D. from Seton Hall University School of Law. He also obtained a Healthcare Compliance Certification from Seton Hall School of Law and completed SEC Law training at the Practicing Law Institute.
Daphne Quimi CPA Vice President, Finance and Corporate Controller
Daphne Quimi joined Amicus in October 2005 and currently serves as Vice President, Finance and Corporate Controller. She brings over 20 years of experience in public accounting and financial reporting. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A from the Stern School of Business of New York University. She is a certified public accountant in New Jersey and a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants.
Ken Valenzano Ph.D. Senior Vice President, Preclinical Research
Ken Valenzano, Ph.D., joined Amicus in July 2005 and currently serves as Senior Vice President, Preclinical Research. He brings over 18 years of experience in the field of pharmacology and drug discovery. Prior to joining Amicus, Dr. Valenzano served in a variety of scientific leadership roles at both Purdue Pharma L.P. and Pharmacopeia, Inc (now Ligand Inc.).
He received a B.S. in Biology from Villanova University, and a Ph.D. from the joint Pharmacology program of Rutgers University and the University of Medicine and Dentistry of NJ where he studied lysosomal biology under the mentorship of Dr. Peter Lobel. His post-doctoral research on G protein-coupled receptor function was conducted in the laboratory of Dr. Marc Caron at Duke University/Howard Hughes Medical Institute.
Julie Yu Ph.D., PMP Vice President, Clinical Operations and Data Management
Julie Yu joined Amicus in February 2008 and currently serves as Vice President, Clinical Operations and Data Management. She brings over 10 years of experience in clinical operations, project management and data management. Prior to joining Amicus, Dr. Yu held roles of increasing responsibility in project management at Merck & Co., Biovail Corporation (now Valeant Pharmaceuticals International), and Juvenile Diabetes Research Foundation. Dr. Yu also worked in bioinformatics, as well as drug discovery software, and cheminformatics databases at Accelrys.
Dr. Yu received a B.Sc. in Immunology and M.Sc. in Pathology from University of Toronto, a Ph.D. from Cambridge University and an MBA from New York University, Stern School of Business. She has also obtained a Project Management Professional certification.